With the Coronavirus pandemic brightly shining the spotlight on the pharmaceutical industry, and scientific disciplines more broadly, the Life Sciences and Health Technologies market is considered one of the largest globally, and is only moving in only one direction.
Following a record-breaking 2021, pharmaceutical, life science and healthcare service companies are continuing to attract investors, fueled by innovations in biotechnology and patient services and ongoing digitalization.
For its part in this sector, Israel has unique assets that constitute potential for global leadership. Israel boasts over 1,500 companies in the life sciences sector, more than 70% in medical devices and digital health, and there have been some headline transactions in the sector in recent years.
We take a deep dive into the Life Sciences landscape in Israel, speaking with thought leaders as we learn more about the latest deals, the drivers behind the industry, the role of VC, and where we are headed. Contributors include (in order of appearance):
Greenberg Traurig’s Adam Snukal,
Lipa Meir & Co.’s Gary Copelovitz,
Gornitzky & Co’s Itamar Mei-Zahav,
S. Horowitz & Co.’s Clifford Davis;
Dechert LLP’s, David Rosenthal
Click here to read the article:
https://www.globallegalmedia.com/israeldesks_sep22/4/index.html
